Skip to main content

dl-Phenylalanine versus imipramine: A double-blind controlled study

Summary

In a double-blind study,dl-phenylalanine (150–200mg/24h) or imipramine (150–200mg/24h) was administered to 40 depressed patients (20 patients in each group) for 30 days.

Diagnoses were established according to the International Classification of Diseases (ICD). The AMP system, the Hamilton Depression Scale and the Bf-S self rating questionnaire (von Zerssen et al., 1974) were used to document psychopathological, neurologic, and somatic changes.

Twenty-seven patients (14 on imipramine, 13 on phenylalanine) completed the 30-day trial. No statistical difference could be found between these two drug treatment groups (Student'st-test) using the Hamilton Depression Scale and the Bf-S self rating questionnaire. Ratings for anxiety were significantly lower in the imipramine group on days 10 and 20, but not on day 30; in addition, sleep disturbances were more influenced by imipramine on days 1, 5, and 10, but not on days 20 and 30.

Separate analysis of psychopathological syndromes as somatic depressive syndrome and retarded depressive syndrome did not show a group difference (0.05 level of significance using a two-way analysis of variance).

It is concluded thatdl-phenylalanine might have substantial antidepressant properties. However, certain methodological considerations still warrant a careful interpretation.

Zusammenfassung

In einer Doppelblindstudie an 40 depressiven Patienten wurde unter stationären Bedingungen entwederdl-Phenylalanin (150–200 mg/die) oder Imipramin (150–200 mg/die) über einen Zeitraum von 30 Tagen appliziert.

Die psychiatrischen Diagnosen wurden gemäß der International Classification of Diseases (ICD) gestellt. Zur Dokumentation der psychopathologischen, neurologischen und somatischen Befunde wurde das AMP-System, die Bf-S-Selbsteinschätzungsskala (v. Zerssen et al., 1974) sowie die Hamilton Depressionsskala verwendet.

27 Patienten (14 unter Imipramin-, 13 unter Phenylalanintherapie) vollendeten die Studie. Mit der Bf-S-Skala und Hamilton-Skala konnten keine statistisch signifikanten (Studentst-Test) Unterschiede zwischen den beiden Behandlungsgruppen gefunden werden. Die Angst-Ratings waren auf der Hamilton-Skala in der Imipramin-Gruppe an Tag 10 und 20 niedriger als in der Phenylalanin-Gruppe, jedoch nicht mehr an Tag 30. Überdies wurden in der Imipramin-Gruppe Schlafstörungen an Tag 1, 5 und 10 günstiger beeinflußt, jedoch nicht mehr an Tag 20 und 30.

Die getrennt durchgeführte Analyse psychopathologischer Syndrome, wie z. B. somalisch-depressives Syndrom und gehemmt-depressives Syndrom, zeigten keine Gruppen-Differenz auf dem 5%-Niveau (2-Wege-Varianzanalyse).

Diese Studie gibt einen weiteren Hinweis auf mögliche antidepressive Eigenschaften vondl-Phenylalanin; gewisse melhodologische Erwägungen jedoch ermöglichen noch nicht eine eindeulige Beurteilung.

This is a preview of subscription content, access via your institution.

Reference

  • Angst, J., Battegay, R., Bente, D., Berner, P., Broeren, W., Cornu, F., Dick, P., Engelmeier, P. H., Heimann, H., Heinrich, H., Hippius, H., Poeldinger, W., Schmidlin, P., Schmitt, W., Weiss, P.: Dokumentationssystem der Arbeitsgemeinschaft für Methodik und Dokumentation in der Psychiatrie (AMP). Arzneim.-Forsch.19, 399–405 (1969)

    Google Scholar 

  • Baumann, U.: Angst, J.: Methodological development of the AMP system. In: Neuropsycho pharmacology, J. R. Boissier, H. Hippius, P. Pichot (Eds.). Proc. of the IX. Congress of the CINP, Paris, 7–12 July, 1974. Excerpta Medica, Amsterdam. New York: American Elsevier Publ. Comp., Inc., 1975

    Google Scholar 

  • Beckmann, H., Dollhofer, P.: Growth hormone secretion under infusion ofdl-phenylalanine. (In preparation)

  • Beckmann, H., Saavedra, J. M.: Urinary excretion of phenylethylamine in depressed patients and healthy controls. (In preparation)

  • Beckmann, H., Strauss, A., Ludolph, E.:dl-phenylalanine in depressed patients: an open study. J. Neurol. Transm.41, 123–134 (1977)

    Google Scholar 

  • Birkmayer, W.: Experimentelle Befunde und neue Aspekte bei extrapyramidalen Erkrankungen. Wien. Z. Nervenheilk.13, 128–139 (1966)

    Google Scholar 

  • Boulton, A., Milward, L.: Separation, detection and quantitative analysis of urinary betaphenylethylamine. J. Chromatog.57, 287–296 (1971)

    Google Scholar 

  • Carlsson, A., Lindquist, M.: Dependence of 5-HT and catecholamine synthesis on concentrations of precursor amino acids in rat brain. Naunyn-Schmiedeberg's Arch. Pharmacol.303, 157–164 (1978)

    Google Scholar 

  • Cramer, H.: Zur Inkorporation von3H-Phenylalanin in Proteine der circumventriculären Organe bei Katzen und Meerschweinchen. Autoradiographische Untersuchung. Exp. Brain Res.11, 343–359 (1970)

    Google Scholar 

  • Fischer, E., Heller, B., Nachon, M., Spatz, H.: Therapy of depression by phenylalanine. Arzneim.-Forsch.25, 132 (1975)

    Google Scholar 

  • Fischer, E., Heller, B., Miró, A. N.:β-phenylethylamine in human urine. Arzneim.-Forsch.18, 1486 (1968)

    Google Scholar 

  • Hamilton, M.: A rating scale for depression. J. Neurol. Neurosurg. Psychiatry23, 56–61 (1960)

    Google Scholar 

  • ICD: International Classification of Diseases. 8. Revision. WHO, Public. No. 8921, Geneva 1974. New York-Heidelberg-Berlin: Springer 1975

    Google Scholar 

  • Inwang, E. E., Mosnaim, A. D., Sabelli, H. C.: Isolation and characterization of phenylethylamine and phenylethanolamine from human brain. J. Neurochem.20, 1469–1473 (1973)

    Google Scholar 

  • Jepson, J. B., Lovenberg, W., Zaltzman, P.: Amine metabolism studied in normal and phenylketonuric humans by monoamine oxidase inhibition. J. Biochem.74, 5 (1960)

    Google Scholar 

  • Lovenberg, W., Weissbach, H., Udenfriend, S.: Aromatic L-amino acid decarboxylase. J. Biol. Chem.237, 89–97 (1962)

    Google Scholar 

  • Morris, J. B., Beck, A.: The efficacy of antidepressant drugs. A review of research (1958–1972). Arch. Gen. Psychiatry30, 667–674 (1974)

    Google Scholar 

  • Mosnaim, A. D., Sabelli, H. C.: Quantitative determination of the brain levels of aβ-phenylethylamine-like substance in control and drug-treated mice. Pharmacologist13, 283–294 (1971)

    Google Scholar 

  • Mosnaim, A. D., Inwang, E. E., Sugarman, J. H., De Martini, W. J., Sabelli, H. C.: Ultraviolet spectrophotometric determination of 2-phenylethylamine in biological samples and its possible correlation with depression. Biol. Psychiat.6, 235–257 (1973)

    Google Scholar 

  • Saavedra, J. M.: Enzymatic isotopic assay for and presence of beta-phenylethylamine in brain. J. Neurochem.22, 211–216 (1974)

    Google Scholar 

  • Sabelli, H. C., Giardina, W. J., Mosnaim, A. D., Sabelli, N. H.: A comparison of the functional roles of norepinephrine, dopamine, and phenylethylamine in the central nervous system. Acta Physiol. Pol.24, 33–40 (1973)

    Google Scholar 

  • Spatz, H., Heller, B., Nachon, M., Fischer, E.: Effects ofd-phenylalanine in clinical picture and phenetylaminuria in depression. Biol. Psychiatry10, 235–238 (1975)

    Google Scholar 

  • Yariyura-Tobias, J. A., Heller, B., Spatz, H., Fischer, E.: Phenylalanine for endogenous depression. J. Orthomolec. Psychiatry3, 80–81 (1974)

    Google Scholar 

  • Zerssen, D. von, Strian, F., Schwarz, D.: Evaluation of depressive states, especially in longitudinal studies. In: Psychological measurements in psychopharmacology. Modern problems of pharmacopsychiatry, P. Pichot, R. Olivier-Martin (Eds.), Vol. 7, pp. 189–202. Basel München-Paris: Karger 1974

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Beckmann, H., Athen, D., Olteanu, M. et al. dl-Phenylalanine versus imipramine: A double-blind controlled study. Arch. Psychiat. Nervenkr. 227, 49–58 (1979). https://doi.org/10.1007/BF00585677

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00585677

Key words

  • dl-Phenytalanine as antidepressant
  • Double-blind trial with imipramine

Schlüsselwörter

  • dl-Phenytalanin als Anlidepressivum
  • Doppelblindstudie gegen Imipramin